The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 7
- 7 renewals
- Median first-year cost
- $979,104
- $6,564,102 in all
- Institutions
- 7
- 7 contact PIs
- Patents
- 9
- from 3 funded projects
Awards by fiscal year
Fiscal years 2014 to 2026.
Most frequent institutions
- ANGEL MEDICAL SYSTEMS, INC.1
- ARONORA, INC.1
- DECIMMUNE THERAPEUTICS, INC1
- HEMOSONICS1
- KEY TECHNOLOGIES, INC.1
and 2 other institutions
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-B (F1))7
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2015 | Novel Methods for Dissolving Blood Clots2R44HL092750-04 | Kang, Andrew HReed, Guy L | TRANSLATIONAL SCIENCES, INC., AZ | First-year cost $1,000,000 | Study section ZHL1 |
| FY2015 | Development of a POC device to guide efficient use of blood products2R44HL103030-04 | Viola, Francesco | HEMOSONICS, VA | First-year cost $999,708 | Study section ZHL1 |
| FY2015 | Pilot Human Study Using Transnasal Cooling on Cardiac Arrest Subjects2R44HL108542-04 | Lane, Benjamin RTandri, Harikrishna | KEY TECHNOLOGIES, INC., MD | First-year cost $937,413 | Study section ZHL1 |
| FY2015 | Commercialization of a Simple Automatic Perfusion System for ECPR2R44HL091606-04 | Mazur, Daniel EdwardNeumar, Robert W. | MC3, INC., MI | First-year cost $813,574 | Study section ZHL1 |
| FY2014 | Humanized Antibody Therapeutic to Improve Cardiac Function Following Myocardial I2R44HL084821-04A1 | Newman, Walter | DECIMMUNE THERAPEUTICS, INC, MA | First-year cost $999,700 | Study section ZHL1 |
| FY2014 | Subcutaneous Acute Ischemia Monitor2R44HL096158-04 | Johnson, StevenKeenan, Dave Lawrence | ANGEL MEDICAL SYSTEMS, INC., NJ | First-year cost $979,104 | Study section ZHL1 |
| FY2014 | Therapeutic Thrombin Analogs2R44HL095315-05 | Gruber, AndrasTucker, Erik Ian | ARONORA, INC., OR | First-year cost $834,603 | Study section ZHL1 |
Patents from its funded projects
9 patents name 3 of the 7 funded projects. The newest 5, by patent number.
- US 12,496,311 (opens the patent at USPTO, a PDF, in a new tab)METHODS FOR SAFELY REDUCING THROMBOPOIETINGranted December 16, 2025 to Aronora, Inc., Oregon Health & Science University and Ionis Pharmaceuticals, Inc.R44HL095315 · ARONORA, INC., OR
- US 11,236,176 (opens the patent at USPTO, a PDF, in a new tab)Serpinf2-Binding Molecules and Method of Use ThereofGranted February 1, 2022 to Translational Sciences, Inc.R44HL092750 · TRANSLATIONAL SCIENCES, INC., AZ
- US 10,137,177 (opens the patent at USPTO, a PDF, in a new tab)Methods and Compositions used in Treating Inflammatory and Autoimmune DiseasesGranted November 27, 2018 to Oregon Health & Science University and Department of Veterans AffairsR44HL095315 · ARONORA, INC., OR
- US 8,954,139 (opens the patent at USPTO, a PDF, in a new tab)ACUTE ISCHEMIA DETECTION BASED ON PARAMETER VALUE RANGE ANALYSISGranted February 10, 2015 to Angel Medical Systems Inc.R44HL096158 · ANGEL MEDICAL SYSTEMS, INC., NJ
- US 8,940,297 (opens the patent at USPTO, a PDF, in a new tab)Expression of anticoagulant thrombin mutants in Escherichia coliGranted January 27, 2015 to Saint Louis UniversityR44HL095315 · ARONORA, INC., OR
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-12-0.3.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.